BILL ANALYSIS

HR4406

NEUTRAL

State-Based Universal Health Care Act of 2025

HR4406 (State-Based Universal Health Care Act of 2025) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR4406 is an early-stage, unfunded authorization bill with no near-term market impact.

No specific company revenue is affected by this bill in its current form.

Market data shows health insurer stocks rallying despite the bill's existence, confirming it is not a threat.

How HR4406 Affects the Market

No actionable market implications for specific tickers. The bill is procedural noise at this stage. Investors should monitor committee hearings or markups for signs of momentum, but none exist today.

Bill Details

Metric	Value
Bill Number	HR4406
Market Sentiment	neutral
Event Date	July 15, 2025
Affected Sectors	Healthcare
Affected Stocks	N/A
Source	View on Congress.gov →

Summary

HR4406 is in very early legislative stages—referred to five committees with 34 cosponsors. No funding is authorized. The bill is not a near-term market factor for any healthcare company.

Full AI Market Analysis

The State-Based Universal Health Care Act of 2025 (HR4406) was introduced on July 15, 2025, and referred to five committees. It has 34 cosponsors, all Democrats. The bill text creates a waiver framework for states to establish universal health care systems, but authorizes no specific funding. No hearings, markups, or votes have occurred. The legislative path is long and uncertain. Major health insurers (UNH, CI, HUM, CVS) have rallied 8-41% in the last 30 days, confirming the market sees no threat from this bill. For-profit hospital operators (HCA, UHS) declined 8-12% in the same period, but this divergence is driven by non-legislative factors. No tickers warrant inclusion because no causal chain can be constructed from this early-stage, unfunded authorization bill to any specific company's revenue. The sponsor (Rep. Khanna, D-CA) is a senior progressive but not a committee chair. The companion bill S2286 is also in early stages. No market-moving action is expected in the current Congress.